Total Payments
$9,022
2024 Payments
$14.92
Companies
15
Transactions
754
Medicare Patients
3,552
Medicare Billing
$1.3M
Payment Breakdown by Category
Food & Beverage$9,006 (99.8%)
Education$16.09 (0.2%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $9,006 | 751 | 99.8% |
| Education | $16.09 | 3 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | $2,772 | 222 | $0 (2020) |
| Sunovion Pharmaceuticals Inc. | $1,139 | 115 | $0 (2021) |
| Allergan, Inc. | $858.04 | 83 | $0 (2020) |
| Takeda Pharmaceuticals U.S.A., Inc. | $826.50 | 80 | $0 (2019) |
| Janssen Pharmaceuticals, Inc | $728.93 | 55 | $0 (2021) |
| Vanda Pharmaceuticals Inc. | $516.37 | 47 | $0 (2020) |
| ABBVIE INC. | $482.32 | 22 | $0 (2024) |
| Alkermes, Inc. | $479.37 | 46 | $0 (2020) |
| Lundbeck LLC | $367.34 | 27 | $0 (2020) |
| Neurocrine Biosciences, Inc. | $316.12 | 20 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $14.92 | 1 | ABBVIE INC. ($14.92) |
| 2022 | $332.54 | 14 | ABBVIE INC. ($332.54) |
| 2021 | $186.88 | 10 | AbbVie Inc. ($134.86) |
| 2020 | $838.07 | 63 | Otsuka America Pharmaceutical, Inc. ($277.21) |
| 2019 | $2,964 | 251 | Otsuka America Pharmaceutical, Inc. ($1,087) |
| 2018 | $2,478 | 218 | Otsuka America Pharmaceutical, Inc. ($810.47) |
| 2017 | $2,208 | 197 | Otsuka America Pharmaceutical, Inc. ($597.69) |
All Payment Transactions
754 individual payment records from CMS Open Payments — Page 1 of 31
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/05/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.92 | General |
| Category: NEUROSCIENCE | ||||||
| 11/23/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $24.19 | General |
| Category: NEUROSCIENCE | ||||||
| 10/28/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $25.07 | General |
| Category: NEUROSCIENCE | ||||||
| 09/16/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $25.57 | General |
| Category: NEUROSCIENCE | ||||||
| 07/22/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $20.81 | General |
| Category: NEUROSCIENCE | ||||||
| 06/24/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $27.56 | General |
| Category: NEUROSCIENCE | ||||||
| 06/10/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $27.31 | General |
| Category: NEUROSCIENCE | ||||||
| 05/26/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $21.44 | General |
| Category: NEUROSCIENCE | ||||||
| 05/13/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $26.01 | General |
| Category: NEUROSCIENCE | ||||||
| 03/28/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $23.33 | General |
| Category: NEUROSCIENCE | ||||||
| 03/18/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $23.33 | General |
| Category: NEUROSCIENCE | ||||||
| 03/14/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $24.24 | General |
| Category: NEUROSCIENCE | ||||||
| 02/23/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $23.33 | General |
| Category: NEUROSCIENCE | ||||||
| 02/18/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $23.33 | General |
| Category: NEUROSCIENCE | ||||||
| 02/10/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $17.02 | General |
| Category: NEUROSCIENCE | ||||||
| 11/22/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $19.27 | General |
| Category: NEUROSCIENCE | ||||||
| 08/13/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $21.47 | General |
| Category: NEUROSCIENCE | ||||||
| 07/07/2021 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug), INVEGA TRINZA | Food and Beverage | In-kind items and services | $15.39 | General |
| Category: Neuroscience | ||||||
| 06/22/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $21.88 | General |
| Category: NEUROSCIENCE | ||||||
| 05/17/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $12.81 | General |
| Category: NEUROSCIENCE | ||||||
| 04/20/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $24.31 | General |
| Category: NEUROSCIENCE | ||||||
| 03/10/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $21.49 | General |
| Category: NEUROSCIENCE | ||||||
| 02/08/2021 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug), INVEGA TRINZA | Food and Beverage | In-kind items and services | $13.74 | General |
| Category: Neuroscience | ||||||
| 01/20/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $13.63 | General |
| Category: NEUROSCIENCE | ||||||
| 01/06/2021 | Sunovion Pharmaceuticals Inc. | LATUDA (Drug) | Food and Beverage | In-kind items and services | $22.89 | General |
| Category: CNS | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 667 | 1,997 | $176,950 | $138,636 |
| 2022 | 8 | 1,033 | 3,745 | $363,439 | $277,046 |
| 2021 | 7 | 920 | 5,867 | $598,769 | $475,123 |
| 2020 | 5 | 932 | 4,856 | $498,003 | $398,169 |
Total Patients
3,552
Total Services
16,465
Medicare Billing
$1.3M
Procedure Codes
25
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 184 | 646 | $71,749 | $52,922 | 73.8% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2023 | 168 | 811 | $56,750 | $49,378 | 87.0% |
| 90836 | Psychotherapy with evaluation and management visit, 45 minutes | Office | 2023 | 135 | 241 | $21,690 | $16,274 | 75.0% |
| 90834 | Psychotherapy, 45 minutes | Office | 2023 | 123 | 170 | $15,770 | $11,933 | 75.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 57 | 129 | $10,991 | $8,130 | 74.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 326 | 1,741 | $193,273 | $138,212 | 71.5% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2022 | 206 | 1,129 | $79,070 | $69,349 | 87.7% |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2022 | 122 | 234 | $25,710 | $25,441 | 99.0% |
| 90836 | Psychotherapy with evaluation and management visit, 45 minutes | Office | 2022 | 172 | 346 | $38,560 | $24,545 | 63.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 97 | 179 | $15,245 | $11,083 | 72.7% |
| 90834 | Psychotherapy, 45 minutes | Office | 2022 | 69 | 73 | $6,611 | $5,183 | 78.4% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2022 | 29 | 31 | $2,790 | $1,739 | 62.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 12 | 12 | $2,180 | $1,495 | 68.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 431 | 4,066 | $451,354 | $348,147 | 77.1% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2021 | 178 | 1,110 | $77,660 | $68,951 | 88.8% |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2021 | 94 | 245 | $26,910 | $26,910 | 100.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 134 | 352 | $29,915 | $22,525 | 75.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 31 | 31 | $5,650 | $4,447 | 78.7% |
| 90836 | Psychotherapy with evaluation and management visit, 45 minutes | Office | 2021 | 25 | 30 | $4,350 | $2,226 | 51.2% |
| 90833 | Psychotherapy performed with evaluation and management visit, 30 minutes | Office | 2021 | 27 | 33 | $2,930 | $1,917 | 65.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 439 | 3,403 | $377,970 | $292,624 | 77.4% |
| 80307 | Testing for presence of drug | Office | 2020 | 199 | 898 | $62,840 | $55,452 | 88.2% |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2020 | 126 | 285 | $31,195 | $31,052 | 99.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 137 | 239 | $20,378 | $14,787 | 72.6% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 31 | 31 | $5,620 | $4,253 | 75.7% |
About Dr. Ileana Berman, MD
Dr. Ileana Berman, MD is a Psychiatry healthcare provider based in Attleboro, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1245277961.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ileana Berman, MD has received a total of $9,022 in payments from pharmaceutical and medical device companies, with $14.92 received in 2024. These payments were reported across 754 transactions from 15 companies. The most common payment nature is "Food and Beverage" ($9,006).
As a Medicare-enrolled provider, Berman has provided services to 3,552 Medicare beneficiaries, totaling 16,465 services with total Medicare billing of $1.3M. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Location Attleboro, MA
- Active Since 06/01/2006
- Last Updated 08/04/2025
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1245277961
Products in Payments
- ABILIFY MAINTENA (Drug) $1,881
- VRAYLAR (Drug) $1,332
- Trintellix (Drug) $1,067
- REXULTI (Drug) $1,062
- LATUDA (Drug) $1,026
- Fanapt (Drug) $459.39
- INVEGA SUSTENNA (Drug) $359.63
- INGREZZA (Drug) $316.12
- Aristada 441 mg (Drug) $288.38
- SPRAVATO (Drug) $206.30
- TRINTELLIX (Drug) $178.37
- INVEGA TRINZA (Drug) $163.00
- ARISTADA (Drug) $130.15
- BROVANA (Drug) $112.92
- Zubsolv (Drug) $95.19
- ABILIFY MYCITE (Drug) $78.67
- HETLIOZ (Drug) $56.98
- VYVANSE (Drug) $56.23
- Vivitrol (Drug) $36.42
- AUSTEDO (Drug) $25.46
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.